0000000001180235

AUTHOR

L. Amaducci

showing 3 related works from this author

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

2018

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks tra…

OncologyTime FactorsAdjuvant Breast cancer Cardiac safety De-escalated treatment TrastuzumabSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentAnthracycline030204 cardiovascular system & hematologyBreast cancerAntineoplastic Agents ImmunologicalErbB-20302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsClinical endpointAnthracyclinesskin and connective tissue diseasesAdjuvantMastectomyAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab;Hazard ratioHematologyMiddle AgedChemotherapy regimenBridged-Ring CompoundImmunologicalLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleTaxoidsTrastuzumab adjuvant breast cancer cardiac safety de-escalated treatmentBreast NeoplasmMastectomyHumanReceptormedicine.drugAdultBridged-Ring Compoundsmedicine.medical_specialtyTime FactorSocio-culturaleBreast NeoplasmsAntineoplastic AgentsDe-escalated treatmentDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerTaxoidInternal medicinemedicineHumansChemotherapyRisk factorAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy ProtocolCardiac safetybusiness.industryTrastuzumabAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab; Hematology; Oncologymedicine.diseaseCardiotoxicityNeoplasm RecurrenceNeoplasm Recurrence LocalbusinessAnnals of Oncology
researchProduct

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

2019

Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. Methods The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death. Results A total of 1244 patients were included. Compared to anatomic stage, the prognost…

OncologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentlcsh:MedicineAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy Protocols8th AJCC030212 general & internal medicineStage (cooking)8th AJCC; Breast cancer; HER2-positive; Prognostic stage; TrastuzumabGeneral MedicineMiddle AgedPrognosisImmunologicalLocal030220 oncology & carcinogenesisFemaleResearch Articlemedicine.drugAdultmedicine.medical_specialtyRandomizationSocio-culturaleAntineoplastic AgentsBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancerInternal medicinePrognostic stagemedicineAdjuvant therapyHumanserbB-2AgedNeoplasm StagingCancer stagingChemotherapybusiness.industrylcsh:RCancerGenes erbB-2Trastuzumabmedicine.diseaseHER2-positive Breast cancer Trastuzumab Prognostic stage 8th AJCCHER2-positiveNeoplasm RecurrenceGenesNeoplasm Recurrence Localbusiness
researchProduct

Associations between cardiac arrhythmia, incident disability in activities of daily living and physical performance: The ilsa study

2020

Background Cardiac arrhythmias are common conditions in older people. Unfortunately, there is limited literature on associations between cardiac arrhythmias and physical performance or disability. We therefore aimed to prospectively investigate associations between cardiac arrhythmias and changes in disability and physical performance during 8 years of follow-up, using data from the Italian Longitudinal Study on Aging (ILSA). Methods Cardiac arrhythmias diagnosis was posed through a screening phase, confirmed by a physician. The onset of disability in activities of daily living (ADL) and the changes in several physical performance tests during follow-up were considered as outcomes. Fully-ad…

DisabilityPhysical activityAtrial fibrillationCardiac arrhythmianot knownPhysical performance
researchProduct